PASSAGE BIO, INC. Estimated Litigation Liability, Current
PASSAGE BIO, INC. (PASG) had Estimated Litigation Liability, Current of $1.00 million as of 2024-09-30, per its 10-Q filed 2024-11-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LitigationReserveCurrent · last filed 2024-11-13
- 2024-09-30: Estimated Litigation Liability, Current $1.00M.
| Period end | Estimated Litigation Liability, Current |
|---|---|
| 2024-09-30 | $1.00M 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |